Damien Pouessel, MD
Institut du Cancer de Montpellier - Val d'Aurelle · CRLC Val d'Aurelle Paul-Lamarque, Montpellier, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Damien Pouessel, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:33 UTC. Open this list on ClinicalTrials.gov
- N/ANCT00875004 · Epoetin Beta in Patients Undergoing Chemotherapy for Solid TumorsInstitut du Cancer de Montpellier - Val d'Aurelle · terminated · Anemia, Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph2NCT00627432 · Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder CancerInstitut du Cancer de Montpellier - Val d'Aurelle · completed · Bladder Cancer · study chair
- Ph2NCT00422786 · Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell CarcinomaThallion Pharmaceuticals · completed · Carcinoma, Renal Cell · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.